Evaluation of compliance through specific interviews: A prospective study of 73 children with acute lymphoblastic leukemia

Jornal de Pediatria

Volumn 81, Issue 3, 2005, Pages 245-250

  De Oliveira, Benigna Maria ^a   Viana, Marcos Borato ^a   De Mattos Arruda, Letícia ^b   Ybarra, Mariana Inês ^c   Romanha, Alvaro José ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Departamento de Pediatria ^*

Author keywords

Chemotherapy; Prognosis; Treatment

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER SURVIVAL; CHILD; EVALUATION; FEMALE; HUMAN; INFANT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; ACUTE LYMPHOCYTIC LEUKEMIA; DISEASE FREE SURVIVAL; FOLLOW UP; PRESCHOOL CHILD; QUESTIONNAIRE; SOCIOECONOMICS; STATISTICS;

ANTINEOPLASTIC ANTIMETABOLITE; MERCAPTOPURINE; METHOTREXATE;

6-MERCAPTOPURINE; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SOCIOECONOMIC FACTORS;

EID: 28344455483     PISSN: 00217557     EISSN: 00217557     Source Type: Journal    
DOI: 10.2223/1346     Document Type: Article

References (27)

1. Pui C-H, Sallan S, Relling MV, Masera G, Evans WE. International childhood acute lymphoblastic leukemia workshop: Sausalito, CA, 30 November - 1 December 2000. Leukemia. 2001;15: 707-15.
2. Uderzo C, Conter V, Dini G, Locatelli F, Miniero R, Tamaro P. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. Haematologica. 2001;86:l-7.
3. Davies HA, Lilleyman JS. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia. Cancer Treat Rev. 1995;21:93-103.
4. Smith SD, Rosen D, Trueworthy RC, Lowman JT. A reliable method for evaluating drug compliance in children with cancer. Cancer. 1979;43:169-73.
5. Lansky SB, Smith SD, Cairns NU, Cairns GF Jr. Psychological correlates of compliance. Am J Pediatr Hematol Oncol. 1983;5:87-92.
6. Tebbi CK, Cummings KM, Zevon MA, Smith L, Richards M, Mallon J. Compliance of pediatric and adolescent cancer patients. Cancer. 1986;58:1179-84.
7. MacDougall LG, Wilson TD, Cohn R, Shuenyane EN, McElligott SE. Compliance with chemotherapy in childhood leukemia in Africa. S Afr Med J. 1989;75:481-4.
8. Festa RS, Tamaroff MH, Chasalow F, Lanzkowsky P. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr. 1992;120:807-11.
9. Snodgrass W, Smith S, Trueworthy R, Vats P, Klopovich P, Kisker S. Pediatric clinical pharmacology of 6-mercaptopurine: lack of compliance as a factor in leukemia relapse. Proc Am Soc Clin Oncol. 1984;3:204.
10. Azeemuddin S, Bharmal FM. Rapid method for evaluating compliance of 6-mercaptopurine therapy in children with leukemia. J Chromatogr. 1988;430:163-9.
11. MacDougall LG, McElligott SE, Ross E, Greeff MC, Poole JE. Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: urinary assays as a measure of drug compliance. Ther Drug Monit. 1992;14:371-5.
12. Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ. 1993;306:1239-40.
13. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? Br J Cancer. 1995;72:1004-6.
14. Lancaster D, Lennard L, Lilleyman JS. Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child. 1997;76:365-6.
15. Lau RC, Matsui D, Greenberg M, Koren G. Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. Med Pediatr Oncol. 1998;30:85-90.
16. Oliveira BM, Viana MB, Zani CL, Romanha AJ. Clinical and laboratory evaluation of compliance in Acute Lymphoblastic Leukaemia. Arch Dis Child. 2004;89:785-8.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Statis Ass 1958;53:457-481.
18. Matsui DM. Drug compliance in pediatrics. Pediatr Clin North Am 1997;44:1-11.
19. Wright EC. Non-Compliance - or how many aunts has Matilda? Lancet 1993;342:909-13.
20. Steiner JF, Earnest MA. The language of medication-taking. Ann Intern Med. 2000;132:926-30.
21. Kyngäs HA, Kroll T, Duff ME. Compliance in adolescents with chronic diseases: a review. J Adolesc Health. 2000;26:379-88.
22. Cameron C. Patient compliance: recognition of factors involved and suggestions for promoting compliance with therapeutic regimens. J Adv Nurs. 1996;24:244-50.
23. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer. 1993;71:3441-9.
24. Lilleyman JS, Lennard L. Non compliance with oral chemotherapy in childhood leukaemia. BMJ. 1996;313:1219-20.
25. Viana MB, Fernandes RAF, Oliveira BM, Murao M, Paes CA, Duarte AA. Nutritional and socio-economic status in the prognosis of childhood acute lymphoblastic leukemia. Haematologica. 2001;86:113-20.
26. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383-6.
27. Spinetta JJ, Masera G, Eden T, Oppenheim D, Martins AG, van Dongen-Melman J, et al. Refusal, non-compliance, and abandonment of treatment in children and adolescents with cancer. A report of the SIOP working committee on psychosocial issues in pediatric oncology. Med Pediatr Oncol. 2002;38:114-17.